
    
      This is a Phase 1, non-randomized, open label, single-dose study to evaluate the effect of
      varying degrees of impaired hepatic function (i.e., mild, moderate, and severe Hepatic
      Impairment (HI)) on the PK, safety, and tolerability of linzagolix and its major metabolite,
      KP017.

      Up to 28 adult female participants will be enrolled.
    
  